Back to search results
NCT07578636

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

Active, Not Recruiting
PHASE1Ages 18–55InterventionalBasic science
Pfizer
~9 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:Oral [14C] PF-07799544Oral Unlabeled PF-07799544IV [14C] PF-07799544

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered.
Measured over Period 1 pre-dose to maximum days 15
+1 more outcome measured

Conditions

Healthy Male Volunteers

Explore related trials

Healthy Volunteers

NCT07578636

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fortrea Clinical Research Unit Inc.

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered.Period 1 pre-dose to maximum days 15

    To characterize the extent of excretion of total radioactivity in urine, feces and vomitus (if any) following administration of a single oral dose of \[14C\]PF-07799544.

  • Metabolic profiling/identification and determination of relative abundance of [14C]PF-07799544 and the metabolites of PF-07799544 in plasma, urine and feces, if possible.Period 1 pre-dose to maximum days 15

    To characterize the metabolic profile and identify the circulating and excreted metabolites of PF- 07799544 following administration of a single oral dose of \[14C\]PF-07799544.